SlideShare a Scribd company logo
1 of 1
Interprete el siguiente documento y establezca la importancia de cada una de las
pruebas que allí se anuncian, elabore un ensayo (una hoja) y preparese para foro de
discusión a desarrollar en la clase de correlación clínica se recomienda para ello
llevar información.
The Global Epidemic of Cardiovascular Disease – Diagnostic Standards
and the Role of the Clinical Laboratory in Primary and Secondary Prevention
and Risk Stratification
Professor M. J. McQueen
There is a global epidemic of atherosclerosis and the future disease burden is probably
underestimated because projections do not account for potential increases in risk factors
such as obesity, diabetes, dyslipidemia, hypertension, smoking, and urbanization.
Population based studies now suggest that 80% to 90% of CVD susceptibility can be
explained by a relatively small number of “classical” risk factors. However, myocardial
infarction occurs in up to 50% of people without significant lipid abnormalities and this
has led to the investigation of novel risk factors such as lipoprotein(a), ApoA1, ApoB,
homocysteine, inflammatory markers, infectious markers, and oxidative stress factors.
The clinical laboratory has a significant role in diagnosis, risk stratification, management
and prognosis in acute coronary syndromes, as well as the primary and secondary
prevention of cardiovascular disease.
Myocardial infarction has been re-defined, giving primacy to the rise and fall of
biochemical markers of myocardial necrosis (troponin/CK-MB) accompanied by at least
one of several symptoms and signs. This has created analytical issues for the clinical
laboratory. The biochemical markers may be cardio-specific but there is still not one
which is ischemic heart disease specific, so various markers for myocardial ischemia
have been investigated. Inflammatory markers have been shown to have prognostic
value in identifying those patients with acute coronary syndrome who are at greater risk
of death or myocardial infarction.
For primary and secondary prevention of cardiovascular disease, lipids and lipoproteins,
LP(a), homocysteine, and many inflammatory markers such as oxidized LDL, IL1,
TNF-α, ICAM, VCAM, selectins, IL6, SAA, and CRP have all been investigated. The
evidence for hsCRP as a risk marker for subsequent cardiovascular events is more clearly
demonstrated in primary prevention than secondary prevention cohorts. Data will be
presented from our Heart Outcomes Prevention Evaluation (HOPE) study relating to
inflammatory markers, multiple infection, heat shock proteins and their relative risk for
subsequent cardiovascular events. There is a need for more research to further define the
approach to therapeutic decision making, using markers of inflammation, infection, and
ventricular dysfunction (eg, natriuretic peptides).
File:shd.CV abstract

More Related Content

Viewers also liked

Diferencias modelo clasico y celular nuevo de la coagulación
Diferencias modelo clasico y celular nuevo de la coagulaciónDiferencias modelo clasico y celular nuevo de la coagulación
Diferencias modelo clasico y celular nuevo de la coagulaciónNanita Perdomo Dominguez
 
2. caso clinico para el blog funcion renal
2. caso clinico para el blog  funcion renal2. caso clinico para el blog  funcion renal
2. caso clinico para el blog funcion renalNanita Perdomo Dominguez
 
Cuestionario de las generalidades hemostasia 2016 a
Cuestionario de las generalidades hemostasia 2016 aCuestionario de las generalidades hemostasia 2016 a
Cuestionario de las generalidades hemostasia 2016 aNanita Perdomo Dominguez
 
Algoritmos de laboratorio para el estudio del estado del hierro
Algoritmos de laboratorio para el estudio del estado del hierroAlgoritmos de laboratorio para el estudio del estado del hierro
Algoritmos de laboratorio para el estudio del estado del hierroNanita Perdomo Dominguez
 
Caso clinico hemostasia anticoagulante lúpico
Caso clinico hemostasia anticoagulante lúpicoCaso clinico hemostasia anticoagulante lúpico
Caso clinico hemostasia anticoagulante lúpicoNanita Perdomo Dominguez
 

Viewers also liked (20)

Blog anemias 2016-a
Blog  anemias 2016-aBlog  anemias 2016-a
Blog anemias 2016-a
 
Funcion renal caso clinico 2013 b
Funcion renal caso clinico 2013 bFuncion renal caso clinico 2013 b
Funcion renal caso clinico 2013 b
 
Caso clínico blog leucemias 2016-a no.1
Caso clínico blog leucemias 2016-a no.1Caso clínico blog leucemias 2016-a no.1
Caso clínico blog leucemias 2016-a no.1
 
Notas microbiologia
Notas microbiologiaNotas microbiologia
Notas microbiologia
 
Caso clinico enf renal
Caso clinico enf renalCaso clinico enf renal
Caso clinico enf renal
 
Articulo chagas
Articulo chagasArticulo chagas
Articulo chagas
 
Caso clinico
Caso clinicoCaso clinico
Caso clinico
 
Diferencias modelo clasico y celular nuevo de la coagulación
Diferencias modelo clasico y celular nuevo de la coagulaciónDiferencias modelo clasico y celular nuevo de la coagulación
Diferencias modelo clasico y celular nuevo de la coagulación
 
Resistencia bacteriana 1
Resistencia bacteriana 1Resistencia bacteriana 1
Resistencia bacteriana 1
 
2. caso clinico para el blog funcion renal
2. caso clinico para el blog  funcion renal2. caso clinico para el blog  funcion renal
2. caso clinico para el blog funcion renal
 
Cuestionario de las generalidades hemostasia 2016 a
Cuestionario de las generalidades hemostasia 2016 aCuestionario de las generalidades hemostasia 2016 a
Cuestionario de las generalidades hemostasia 2016 a
 
Apendicitis y lma
Apendicitis y lmaApendicitis y lma
Apendicitis y lma
 
Caso clinico blog abril 1 de 2016
Caso clinico blog abril 1 de 2016Caso clinico blog abril 1 de 2016
Caso clinico blog abril 1 de 2016
 
1. actividad de funcion renal
1. actividad de funcion renal1. actividad de funcion renal
1. actividad de funcion renal
 
Algoritmos de laboratorio para el estudio del estado del hierro
Algoritmos de laboratorio para el estudio del estado del hierroAlgoritmos de laboratorio para el estudio del estado del hierro
Algoritmos de laboratorio para el estudio del estado del hierro
 
Caso clinico blog abril 1 de 2016
Caso clinico blog abril 1 de 2016Caso clinico blog abril 1 de 2016
Caso clinico blog abril 1 de 2016
 
Pancreas clase ver
Pancreas clase verPancreas clase ver
Pancreas clase ver
 
Fisiologia pancreas endocrino
Fisiologia pancreas endocrinoFisiologia pancreas endocrino
Fisiologia pancreas endocrino
 
Enfermedades del pancreas exocrino
Enfermedades del pancreas exocrinoEnfermedades del pancreas exocrino
Enfermedades del pancreas exocrino
 
Caso clinico hemostasia anticoagulante lúpico
Caso clinico hemostasia anticoagulante lúpicoCaso clinico hemostasia anticoagulante lúpico
Caso clinico hemostasia anticoagulante lúpico
 

Similar to La epidemia global de la enfermedad cardiovascuar version 2

Caso clinico la epidemia global de la enfermedad cardiovascuar version
Caso clinico la epidemia global de la enfermedad cardiovascuar versionCaso clinico la epidemia global de la enfermedad cardiovascuar version
Caso clinico la epidemia global de la enfermedad cardiovascuar versionYOJANNA PERDOMO DOMINGUEZ
 
259 crp as a risk factor
259 crp as a risk factor259 crp as a risk factor
259 crp as a risk factorSHAPE Society
 
Beyond Framingham
Beyond FraminghamBeyond Framingham
Beyond Framinghamhospital
 
234 aha 2002 guideline, 1997 or 2002
234 aha 2002 guideline, 1997 or 2002234 aha 2002 guideline, 1997 or 2002
234 aha 2002 guideline, 1997 or 2002SHAPE Society
 
Marc Penn, MD, PhD, FACC - Trials and Tribulations of Assessing CVD Risk in ...
Marc Penn,  MD, PhD, FACC - Trials and Tribulations of Assessing CVD Risk in ...Marc Penn,  MD, PhD, FACC - Trials and Tribulations of Assessing CVD Risk in ...
Marc Penn, MD, PhD, FACC - Trials and Tribulations of Assessing CVD Risk in ...Cleveland HeartLab, Inc.
 
Diagnosis of Early Risks, Management of Risks, and Reduction of Vascular Dise...
Diagnosis of Early Risks, Management of Risks, and Reduction of Vascular Dise...Diagnosis of Early Risks, Management of Risks, and Reduction of Vascular Dise...
Diagnosis of Early Risks, Management of Risks, and Reduction of Vascular Dise...asclepiuspdfs
 
Lipoprotein associated phospholipase a2
Lipoprotein associated phospholipase a2Lipoprotein associated phospholipase a2
Lipoprotein associated phospholipase a2Saroj Kundan
 
251 computed tomographic coronary artery calcium
251 computed tomographic coronary artery calcium251 computed tomographic coronary artery calcium
251 computed tomographic coronary artery calciumSHAPE Society
 
10.1007@s10067 018-04416-x
10.1007@s10067 018-04416-x10.1007@s10067 018-04416-x
10.1007@s10067 018-04416-xAndi Wahyudi
 
Presentatie Prof. dr. Deckers en Prof. dr. Bots
Presentatie Prof. dr. Deckers en Prof. dr. BotsPresentatie Prof. dr. Deckers en Prof. dr. Bots
Presentatie Prof. dr. Deckers en Prof. dr. BotsCVON
 

Similar to La epidemia global de la enfermedad cardiovascuar version 2 (20)

Caso clinico la epidemia global de la enfermedad cardiovascuar version
Caso clinico la epidemia global de la enfermedad cardiovascuar versionCaso clinico la epidemia global de la enfermedad cardiovascuar version
Caso clinico la epidemia global de la enfermedad cardiovascuar version
 
259 crp as a risk factor
259 crp as a risk factor259 crp as a risk factor
259 crp as a risk factor
 
Esv2n47
Esv2n47Esv2n47
Esv2n47
 
259 crp as a risk factor
259 crp as a risk factor259 crp as a risk factor
259 crp as a risk factor
 
Beyond Framingham
Beyond FraminghamBeyond Framingham
Beyond Framingham
 
234 aha 2002 guideline, 1997 or 2002
234 aha 2002 guideline, 1997 or 2002234 aha 2002 guideline, 1997 or 2002
234 aha 2002 guideline, 1997 or 2002
 
234 aha 2002 guideline, 1997 or 2002
234 aha 2002 guideline, 1997 or 2002234 aha 2002 guideline, 1997 or 2002
234 aha 2002 guideline, 1997 or 2002
 
Esv2n29
Esv2n29Esv2n29
Esv2n29
 
Marc Penn, MD, PhD, FACC - Trials and Tribulations of Assessing CVD Risk in ...
Marc Penn,  MD, PhD, FACC - Trials and Tribulations of Assessing CVD Risk in ...Marc Penn,  MD, PhD, FACC - Trials and Tribulations of Assessing CVD Risk in ...
Marc Penn, MD, PhD, FACC - Trials and Tribulations of Assessing CVD Risk in ...
 
Diagnosis of Early Risks, Management of Risks, and Reduction of Vascular Dise...
Diagnosis of Early Risks, Management of Risks, and Reduction of Vascular Dise...Diagnosis of Early Risks, Management of Risks, and Reduction of Vascular Dise...
Diagnosis of Early Risks, Management of Risks, and Reduction of Vascular Dise...
 
Lipoprotein associated phospholipase a2
Lipoprotein associated phospholipase a2Lipoprotein associated phospholipase a2
Lipoprotein associated phospholipase a2
 
Herrick et al _JCDR 2014
Herrick et al _JCDR 2014Herrick et al _JCDR 2014
Herrick et al _JCDR 2014
 
Fuster aha-2005-dallas-biomarkers,
Fuster  aha-2005-dallas-biomarkers,Fuster  aha-2005-dallas-biomarkers,
Fuster aha-2005-dallas-biomarkers,
 
251 computed tomographic coronary artery calcium
251 computed tomographic coronary artery calcium251 computed tomographic coronary artery calcium
251 computed tomographic coronary artery calcium
 
251 computed tomographic coronary artery calcium
251 computed tomographic coronary artery calcium251 computed tomographic coronary artery calcium
251 computed tomographic coronary artery calcium
 
Es v2n43
Es v2n43Es v2n43
Es v2n43
 
10.1007@s10067 018-04416-x
10.1007@s10067 018-04416-x10.1007@s10067 018-04416-x
10.1007@s10067 018-04416-x
 
BIOMARKERS IN HF.pptx
BIOMARKERS IN HF.pptxBIOMARKERS IN HF.pptx
BIOMARKERS IN HF.pptx
 
CVD-Report-V1.pdf
CVD-Report-V1.pdfCVD-Report-V1.pdf
CVD-Report-V1.pdf
 
Presentatie Prof. dr. Deckers en Prof. dr. Bots
Presentatie Prof. dr. Deckers en Prof. dr. BotsPresentatie Prof. dr. Deckers en Prof. dr. Bots
Presentatie Prof. dr. Deckers en Prof. dr. Bots
 

More from Nanita Perdomo Dominguez (13)

Fisiologia de la secrecion pancreatica
Fisiologia de la secrecion pancreaticaFisiologia de la secrecion pancreatica
Fisiologia de la secrecion pancreatica
 
Enfermedad diarreica
Enfermedad diarreicaEnfermedad diarreica
Enfermedad diarreica
 
Equilibrio ácido base- actualizado correlación
Equilibrio ácido base- actualizado correlaciónEquilibrio ácido base- actualizado correlación
Equilibrio ácido base- actualizado correlación
 
Caso clínico blog leucemias 2016-a no. 2
Caso clínico blog leucemias 2016-a no. 2Caso clínico blog leucemias 2016-a no. 2
Caso clínico blog leucemias 2016-a no. 2
 
Resistencia bacteriana
Resistencia bacterianaResistencia bacteriana
Resistencia bacteriana
 
Caso clínico de resistencia bacteriana (1)
Caso clínico de resistencia bacteriana (1)Caso clínico de resistencia bacteriana (1)
Caso clínico de resistencia bacteriana (1)
 
Presentacion tripanosomiais leishmaniasis
Presentacion tripanosomiais leishmaniasisPresentacion tripanosomiais leishmaniasis
Presentacion tripanosomiais leishmaniasis
 
Funcion hepatica jhoalmis
Funcion hepatica jhoalmisFuncion hepatica jhoalmis
Funcion hepatica jhoalmis
 
Funcion hepatica jhoalmis
Funcion hepatica jhoalmisFuncion hepatica jhoalmis
Funcion hepatica jhoalmis
 
Anemias correlación clínica 2016 a
Anemias  correlación clínica 2016 aAnemias  correlación clínica 2016 a
Anemias correlación clínica 2016 a
 
Funcion hepatica caso clinico
Funcion hepatica caso clinicoFuncion hepatica caso clinico
Funcion hepatica caso clinico
 
Diarreas 2 copia
Diarreas 2   copiaDiarreas 2   copia
Diarreas 2 copia
 
Coprocultivo
CoprocultivoCoprocultivo
Coprocultivo
 

La epidemia global de la enfermedad cardiovascuar version 2

  • 1. Interprete el siguiente documento y establezca la importancia de cada una de las pruebas que allí se anuncian, elabore un ensayo (una hoja) y preparese para foro de discusión a desarrollar en la clase de correlación clínica se recomienda para ello llevar información. The Global Epidemic of Cardiovascular Disease – Diagnostic Standards and the Role of the Clinical Laboratory in Primary and Secondary Prevention and Risk Stratification Professor M. J. McQueen There is a global epidemic of atherosclerosis and the future disease burden is probably underestimated because projections do not account for potential increases in risk factors such as obesity, diabetes, dyslipidemia, hypertension, smoking, and urbanization. Population based studies now suggest that 80% to 90% of CVD susceptibility can be explained by a relatively small number of “classical” risk factors. However, myocardial infarction occurs in up to 50% of people without significant lipid abnormalities and this has led to the investigation of novel risk factors such as lipoprotein(a), ApoA1, ApoB, homocysteine, inflammatory markers, infectious markers, and oxidative stress factors. The clinical laboratory has a significant role in diagnosis, risk stratification, management and prognosis in acute coronary syndromes, as well as the primary and secondary prevention of cardiovascular disease. Myocardial infarction has been re-defined, giving primacy to the rise and fall of biochemical markers of myocardial necrosis (troponin/CK-MB) accompanied by at least one of several symptoms and signs. This has created analytical issues for the clinical laboratory. The biochemical markers may be cardio-specific but there is still not one which is ischemic heart disease specific, so various markers for myocardial ischemia have been investigated. Inflammatory markers have been shown to have prognostic value in identifying those patients with acute coronary syndrome who are at greater risk of death or myocardial infarction. For primary and secondary prevention of cardiovascular disease, lipids and lipoproteins, LP(a), homocysteine, and many inflammatory markers such as oxidized LDL, IL1, TNF-α, ICAM, VCAM, selectins, IL6, SAA, and CRP have all been investigated. The evidence for hsCRP as a risk marker for subsequent cardiovascular events is more clearly demonstrated in primary prevention than secondary prevention cohorts. Data will be presented from our Heart Outcomes Prevention Evaluation (HOPE) study relating to inflammatory markers, multiple infection, heat shock proteins and their relative risk for subsequent cardiovascular events. There is a need for more research to further define the approach to therapeutic decision making, using markers of inflammation, infection, and ventricular dysfunction (eg, natriuretic peptides). File:shd.CV abstract